CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 35 enrolled
Drug / intervention
Triamcinolone Acetonide Extended-Release Injectable Suspensiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04261049
NCT04261049Phase 1Completed
CompareCT.gov

Effect of ZILRETTA Injection on Neuromuscular Function, Gait Biomechanics and Physical Performance

University of North Carolina, Chapel Hill·interventional·Posted Feb 7, 2020·Updated May 20, 2022

In Brief

A Phase 1 clinical trial evaluating Triamcinolone Acetonide Extended-Release Injectable Suspension for Osteoarthritis, Knee. Completed, enrolled 35 participants across 1 site.

Detailed Summary

The purpose of this study is to examine the pre-post effects of a single ZILRETTA knee injection on physiological measures of self-reported pain and disability, physical performance, and physical activity in individuals with knee osteoarthritis (OA). The investigators will recruit 35 symptomatic knee OA patients for this study. All data will be collected prior to injection (baseline), as well as at 4 (post 1) and 8-week follow-ups (post 2).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis, Knee
CountriesUnited States
CollaboratorsPacira Pharmaceuticals, Inc

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedFeb 7, 2020
Enrollment StartAug 1, 2020
Primary CompletionJan 10, 2022
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 6.4 years ago

Interventions

Triamcinolone Acetonide Extended-Release Injectable Suspensiondrug

A single ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) intra-articular knee injection.